References
- Howe RA, Wooton M, Walsh TR, Bennett PM, MacGowan AP. Expression and detection of hetero-van-comycin resistance in Staphylococcus aureus. J Antimicrob Chemother 1999; 44: 675–678.
- Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. Heterogeneous vancomycin resistance in methicillin-resis-tant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866–869.
- Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670–1673.
- Geisel R, Schmitz FJ, Thomas et al. Emergence of het-erogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Düsseldorf area. J Antimicrob Chemother 1999; 43: 846–848.
- Carbon C. Costs of treating infections caused by methi-cillin-resistant staphylococci and vancomycin-resistant entero-cocci. J Antimicrob Chemother 1999; 44 (Suppl A): 31-36.
- Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: A cost-benefit analysis in an intensive care unit. JAMA 1999; 282: 1745–1751.
- Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999; 340: 493–501.
- Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003; 348: 1342–1347.
- Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methi-cillin-resistant Staphylococcus aureus infection. N Engl J Med. 1999; 340: 517–523.
- Mouton JW, Jansz AR. The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. Clin Microbiol Infect 2001; 7: 486–491.
- Harding I, Felmingham D. PROTEKT Years 1-3 (1999-2002): Study design and methodology. J Chemother 2004; 16 (Suppl. 6): 9-18.
- Kohner PC, Patel R, Uhl JR et al. Comparison of agar dilution, broth microdilution„ E-test, disk diffusion, and auto-mated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin. J Clin Microbiol 1997; 35: 3258–3263.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 10th International Suppl., M100-S10 (M7). Wayne: NCCLS, 2000.
- Walsh TR, Bolmstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439–2444.
- National Committee on Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 12th International Suppl., M100-512 Vol 22, No.1, NCCLS; 940 West Valley Road, Wayne, Pennsylvania, USA, 2002.
- Phillips OA, Udo EE, Ali AAM, Mokaddas EM. Comparative antimicrobial activities of linezolid and van-comycin against Gram-positive clinical isolates from hospitals in Kuwait. Med Principles Pract 2001; 10: 177–181.
- Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezol-id. Linezolid Study Group. J Antimicrob Chemother 2000; 46: 931–940.
- Reinert RR. Resistance phenotypes and multi-drug resistance in Streptococcus pneumoniae (PROTEKT Years 1-3[19999-2002]). J Chemother 2004; 16 (Suppl. 6): 35-48.
- Schito GC. Resistance trends in Streptococcus pneu-moniae (PROTEKT Years 1-3 [1999-2002]). J Chemother 2004; 16 (Suppl. 6): 19-34.
- Ahmed K, Martinez G, Wilson S, et al. The prevalence and clonal diversity of penicillin-resistant Streptococcus pneu-moniae in Kuwait. Epidem Infect 2000; 125: 573–581.
- Mokaddas EM, Wilson S, Sanyal SC. Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait. J Chemother 2001; 13: 154–160.
- Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among iso-lates of Streptococcus pneumoniae from the PROTEKT sur-veillance study, and comparative in vitro activity of ketolide, telithromycin. J Antimicrob Chemother 2002; 50 (Suppl. 1): 25-37.
- Kohno S, Hoban D, and The PROTEKT Surveillance Study Group. Comparative in vitro activity of telithromycin and I3-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: Data from the first year of PROTEKT (1999-2000). J Chemother 2003; 15: 33–341.